Learn more about UC TechAlerts – Subscribe to categories and get notified of new UC technologies

Browse Category: Medical > Disease: Dermatology

Categories

[Search within category]

Compound for the Prevention Of Rosacea Inflammation

Rosacea is a chronic skin condition characterized by recurrent episodes of flushing, erythema, vasodilation, telangiectasia, edema, papules, pustules, hyperplasia, fibroplasia, itching, burning, pain, and skin tightness. Symptoms of rosacea are exacerbated by sun exposure, hot weather, immersion in hot water, high humidity, sweating, exercise, emotional stress, and spicy food. The skin condition usually begins between the ages of 30 to 50 and occurs more frequently in women than men. An estimated 16 million people are affected by rosacea inflammation in the United States. Oral and topical antibiotics are usually the first line of treatments prescribed for rosacea patients. However, they can cause serious side effects in some patients and do not address the underlying condition. Topical application of steroids may also help alleviate the symptoms, but it can also aggravate the condition. In addition, long term treatments can be inconvenient, lasting for as long as two years.

Inflammation Induction and Tissue Repair

Inflammation is an important response for resisting infection and repairing damage. Under circumstances such as cancer or infectious diseases, stimulation of the inflammatory response is therapeutic. It is unclear why the existing adjuvant therapies tend to be more effective in the treatment of some disease, such as breast and colon cancer, than others. This invention identifies additional ways to stimulate the immune response and induce inflammation in order to accelerate repair of disease-related tissue injury.

Firmocidin, A New Small-Molecule Antibiotic to Treat MRSA, Staph, and Streptococcus Infections

Methicillin-resistant S. aureus (MRSA), a bacterial strain that is highly resistant to some antibiotics, is a major problem at healthcare delivery sites such as hospitals and health clinics. According to the U.S. Centers for Disease Control and Prevention, in 2005 there were an estimated 478,000 hospitalizations with a diagnosis of S. aureus infection in U.S. hospitals. Of these, approximately 278,000 hospitalizations were related to MRSA. The estimated number of people developing a serious MRSA infection (i.e., invasive) in 2005 was greater than 94,000. Approximately 19,000 persons died during a hospital stay related to these serious MRSA infections.Serious MRSA disease is still predominantly related to exposures to healthcare delivery. About 85 percent of all invasive MRSA infections were associated with healthcare, and of those, about two-thirds occurred outside of the hospital, while about one third occurred during hospitalization.

Anti-inflammatory compounds for dermatology and chronic inflammation

While inflammation is a beneficial component of the body’s response to harmful stimuli, prolonged or excessive inflammation triggers a wide variety of diseases. Current anti-inflammatory drugs (steroids, NSAIDs and immune selective anti-inflammatory derivatives) have undesirable side effects and for many indications including dermatology, drugs that act by a novel MOA may be more efficacious.

A New Method To Accelerate Tissue and Wound Healing Rates and Reduce Swelling and Scar Formation

 Skin wounds are today typically treated with surface antibiotics and many different forms of bandages enriched with antibiotics and growth factors. There are numerous wound healing agents currently being used today.

Natural Products for Cancer Therapeutics

Brief description not available

Vaccines Against Acne and Acne-Associated Diseases

Propionibacterium acnes (P. acnes) bacteria is involved in many human polymicrobial diseases. It is the causative agent in acne vulgaris, a human polymicrobial disease. Acne vulgaris is the most common skin disease, affecting more than 85 percent of people at some time during their lives and currently affects more than fifty million people in the U.S. Current antibiotic therapy for acne lesions provides a non-specific treatment that kills the majority of skin bacteria and impacts the homeostasis of skin- and intestinal-resident flora. Acne vulgaris can result in severe inflammatory lesions that are highly associated with P. acnes infection. There are no appropriate therapeutic modalities that are long-lasting and systemically effective and that specifically suppress P. acnes-induced pathogenesis and inflammation. In addition, these bacteria have the ability to trigger inflammatory responses. Many antibiotics have been used for acne treatment, but these antibiotics in general are non-specific, short lasting, and normally are applied when acne lesions have already occurred (such as in late stages of acne). Available topical treatments for acne lesions, including drugs, are palliative and effective only while treatment is maintained. When treatment is discontinued, increased acne gain inevitably results.

  • Go to Page: